ANBT
NBIX icon

American National Bank & Trust’s Neurocrine Biosciences NBIX Stock Holding History

American National Bank & Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27
Closed -$3.39K – 674
2025
Q2 		$3.39K Sell
27
-24
-47% -$2.75K ﹤0.01% 601
2025
Q1 		$5.64K Sell
51
-328
-87% -$41.6K ﹤0.01% 505
2024
Q4 		$51.7K Buy
+379
New +$46.9K 0.01% 316

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American National Bank & Trust's NBIX Position: Q3 2025 in Review

American National Bank & Trust sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 27 shares — an estimated $3.39K sold.

American National Bank & Trust first reported a position in NBIX in Q4 2024 and held it in 3 quarters. The position peaked at $51.7K in Q4 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • American National Bank & Trust reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • American National Bank & Trust sold 27 Neurocrine Biosciences shares in Q3 2025, an estimated $3.39K.
  • American National Bank & Trust first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 3 quarters.
  • American National Bank & Trust's Neurocrine Biosciences position peaked at $51.7K in Q4 2024.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on American National Bank & Trust's 13F filing for Q3 2025, filed 21 Oct 2025.